Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease.

Trial Profile

Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2012

At a glance

  • Drugs Colchicine (Primary)
  • Indications Gout
  • Focus Pharmacokinetics
  • Sponsors URL Pharma
  • Most Recent Events

    • 11 Oct 2012 Actual initiation date changed from Mar 2010 to May 2010 as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Trial phase changed from I to IV as reported by ClinicalTrials.gov.
    • 18 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top